Diagnosis and management of insulinoma: current best practice and ongoing developments

References

• Service FJ. Hypoglycemic disorders. N Engl J Med. 1995;332(17):1144–1152.
   PubMed Web of Science ®Google Scholar
• Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg. 1935;101(6):1299–1335.
   Google Scholar
• Grant CS. Insulinoma. Baillieres Clin Gastroenterol. 1996;10(4):645–671.
   Google Scholar
• Richards ML, Gauger PG, Thompson NW, Kloos RG, Giordano TJ. Pitfalls in the surgical treatment of insulinoma. Surgery. 2002;132(6):1040–1049; discussion 1049.
   Web of Science ®Google Scholar
• Boukhman MB, Karam JM, Shaver J, et al. Localization of insulinomas. Arch Surg. 1999;134(8):818–822; discussion 822–823.
   Google Scholar
• Boukhman MP, Karam JH, Shaver J, Siperstein AE, Duh QY, Clark OH. Insulinoma – experience from 1950 to 1995. West J Med. 1998;169(2):98–104.
   Google Scholar
• Callender GG, Rich TA, Perrier ND. Multiple endocrine neoplasia syndromes. Surg Clin N Am. 2008;88(4):863–895.
   Web of Science ®Google Scholar
• O’Riordain DS, O’Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg. 1994;18(4):488–493; discussion 493–494.
   PubMed Web of Science ®Google Scholar
• Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6(2):229–237.
   Web of Science ®Google Scholar
• Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106(3):307–310.
   PubMed Web of Science ®Google Scholar
• Kennedy EP, Brody JR, Yeo CJ. Neoplasms of the endocrine pancreas. In: Mulholland MW, Lillemoe KD, Doherty GM, Maier RV, Simeone DM, Upchurch GR Jr, editors. Greenfield’s Surgery Scientific Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:857–871.
   Google Scholar
• Vig S, Lewis M, Foster KJ, Stacey-Clear A. Lessons to be learned: a case study approach insulinoma presenting as a change in personality. J R Soc Promot Health. 2001;121(1):56–61.
   PubMedGoogle Scholar
• Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009;89(5):1105–1121.
   Web of Science ®Google Scholar
• Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85(9):3222–3226.
   Web of Science ®Google Scholar
• Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675–686.
   PubMed Web of Science ®Google Scholar
• Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg. 1999;189(4):368–373.
   Web of Science ®Google Scholar
• Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab. 2009;94(4):1074–1080.
   Web of Science ®Google Scholar
• Brown CK, Bartlett DL, Doppman JL, et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery. 1997;122(6):1189–1193; discussion 1193–1194.
   Web of Science ®Google Scholar
• Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123(4):269–273.
   Web of Science ®Google Scholar
• Finlayson E, Clark OH. Surgical treatment of insulinomas. Surg Clin North Am. 2004;84(3):775–785.
   Web of Science ®Google Scholar
• Wayne M, Steele J, Iskandar M, Cooperman A. Robotic pancreatic surgery is no substitute for experience and clinical judgment: an initial experience and literature review. World J Surg Oncol. 2013;11:160.
   Web of Science ®Google Scholar
• Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124(6):1056–1061; discussion 1061–1062.
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Libutti SK, Alexander HR, et al. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg. 2002;194(6):761–764.
   Web of Science ®Google Scholar
• Berends FJ, Cuesta MA, Kazemier G, et al. Laparoscopic detection and resection of insulinomas. Surgery. 2000;128(3):386–391.
   Web of Science ®Google Scholar
• Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol. 2011;103(2):169–174.
   PubMed Web of Science ®Google Scholar
• Grover AC, Skarulis M, Alexander HR, et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery. 2005;138(6):1003–1008; discussion 1008.
   Web of Science ®Google Scholar
• Simon D, Starke A, Goretzki PE, Roeher HD. Reoperative surgery for organic hyperinsulinism: indications and operative strategy. World J Surg. 1998;22(7):666–671; discussion 671–672.
   Web of Science ®Google Scholar
• Goode PN, Farndon JR, Anderson J, Johnston IDA, Morte JA. Diazoxide in the management of patients with insulinoma. World J Surg. 1986;10(4):586–592.
   PubMed Web of Science ®Google Scholar
• Fajans SS, Floyd JC, Thiffault CA, Knopf RF, Harrison TS, Conn JW. Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man. Ann N Y Acad Sci. 1968;150(2):261–280.
   Google Scholar
• Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother. 2002;3(6):643–656.
   Google Scholar
• Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152(5):757–767.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, CwikŁa JB, et al; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
   PubMed Web of Science ®Google Scholar
• Ferrer-García JC, Iranzo González-Cruz V, Navas-DeSolís S, et al. Management of malignant insulinoma. Clin Transl Oncol. 2013;15(9):725–731.
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104(2):264–272.
   Web of Science ®Google Scholar
• Raymond E, Dahan L. Raoul JL. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523.
   PubMed Web of Science ®Google Scholar